Synergia Medical is pleased to announce that they have been awarded the Prix Galien 2023 in Belgium for promising medical devices.
Synergia Medical today announced the successful completion of an additional €3.8 million of Series B funding bringing the total to €12.8 million. This allows Synergia Medical to prepare for First-In-Human clinical trials planned for 2024.
Synergia Medical announced the appointment of Dan Scherrer as Chief Operating Officer. Dan Scherrer brings over 20 years of experience manufacturing, supply chain, quality management and product development in the medical device field.
Synergia Medical announced that it has been awarded a €2.5 million grant from the EIC Accelerator program with the potential for an equity investment from the EU in the future Series C fund raising of a further €7.5 million.
Synergia Medical announced the successful completion of a €9 million Series B funding round. This allows Synergia Medical to prepare for First-In-Human clinical trials planned for 2023 and the IDE (Investigational Device Exemption) submission to the FDA in the USA. IDE allows an investigational device to be used in a clinical study to collect safety and efficacy data.
The Synergia Medical team was delighted to display 4 scientific posters at INS Barcelona 2022.
Synergia Medical is proud to announce the renewal of its ISO 13485 – Medical Devices – Quality Management System certification.
Synergia Medical is pleased to welcome Denis Gestin to its Board of Directors.
Synergia Medical is proud to have been selected as one of the 5 finalists of the 9th Annual Shark Tank Competition organized by the Epilepsy Foundation.
We are very proud to announce that we have been selected for the MedTech Innovator Annual Accelerator and Showcase program.
Synergia Medical proudly announces the appointment of Mrs. Sophie Baratte as Chair of the Board.
We are very pleased to announce that Yves Jongen and Jacques van Rijckevorsel have joined Synergia Medical's Board of directors.